



IFAC 18th World Congress
Milano, August 28 – September 2, 2011



Robust Tight Glycaemic Control of ICU Patients

**Levente Kovács¹, Péter Szalay¹, Balázs Benyó¹,
J. Geoffrey Chase²**

¹ **Dept. of Control Engineering and Information Technology
Budapest Univ. of Technology and Economics, Hungary**

² **Dept. of Mechanical Engineering, Centre for Bio-Engineering
University of Canterbury, Christchurch, New Zealand**


Contents



- Introduction
 - Motivation
 - ICU models
- Investigated model
- μ -Synthesis method
- LPV & qALPV modeling
- Results
- Conclusions

ICU & TGC

- Hypoglycaemia & insulin resistance \implies \nearrow morbidity & mortality¹
- TGC can reduce adverse outcomes² (and costs³)
- Multidimensional problem (avoid hypo, variability, CHO, etc.)⁴
- Repeatability problem⁵
- Variability in ICU patients presents ideal application field for model-based automation of insulin infusions for TGC⁶



ICU Model

1 – SE Capes et al. (2000). *Lancet*, **355**(9206): 773-778.

2 – J Chase et al. (2008). *Critical Care*, 12:R49.

3 – Van den Berghe et al. (2006). *Crit Care Med*, **34**(3):612-616.

4 – U Pielmeier et al. (2010). *UKACC Conf*, 839-844.

5 – Griesdale et al. (2009) *Can Med Assoc J*, 180(8):821-827.

6 – J Lin et al. (2008). *CMPB*, **89**(2):141-152.

Models¹

- Minimal model: Bergman-model (1979, 1981)
- ICU: Canterbury-model (2004, 2008, 2010)
van Herpe-model (2006)

Challenges¹:



¹ – L Kovacs et al. (2010). *UKACC Conf.* 577-582.

Canterbury-model ¹



$$\dot{G}(t) = -p_G G(t) - S_I(t)(G(t) + G_E) \frac{Q(t)}{1 + \alpha_G Q(t)} + P(t)$$

$$\dot{Q}(t) = kI(t) - kQ(t)$$

$$\dot{I}(t) = -\frac{nI(t)}{1 + \alpha_I I(t)} + \frac{u_{ex}(t)}{V_I}$$

- Insulin bounded to interstitial sites
- Insulin losses to the liver and kidneys
- Saturation dynamics
- Insulin sensitivity metric

1 – X.W. Wong et al. (2006). *Med Eng & Physics*, 28:665-681.

Redefined Canterbury-model ¹



$$\dot{G}(t) = -p_G \underbrace{G(t)} - S_I(t) \frac{G(t)Q(t)}{1 + \alpha_G Q(t)} + \frac{P(t) + EGP_b - CNS}{V_G}$$

$$\dot{Q}(t) = kI(t) - kQ(t)$$

Actual plasma glucose concentration

$$\dot{I}(t) = -\frac{nI(t)}{1 + \alpha_I I(t)} + \frac{u_{ex}(t)}{V_I} + \underbrace{\frac{u_{end}(t)}{V_I}}$$

Endogenous insulin production

$$\dot{P}_1(t) = D(t) - d_1 P_1(t)$$

$$\dot{P}_2(t) = d_1 P_1(t) - \min\{d_2 P_2(t), P_{max}\}$$

$$P(t) = \min\{d_2 P_2(t), P_{max}\}$$

Glucose absorption during enteral feeding (in reality are linear f.)

$$u_{end}(t) = k_1 \exp\left(\frac{-k_2 I(t)}{k_3}\right)$$

¹ – F. Suhaimi et al. (2010). *UKACC Conf*, 1037-1042.

Aim of robust H_∞ control



Basic control requirements:

stability & performance

good command following

disturbance rejection

← uncertainty

Nominal Performance & Robust Stability

H_∞ – minimization in „worst case”

Rationalism (exact formulation)

+ Empiricism (based on expertise)

μ -Synthesis method



M (P-K) structure

$$\begin{bmatrix} e \\ \tilde{z} \end{bmatrix} = \begin{bmatrix} M_{11} & M_{12} \\ M_{21} & M_{22} \end{bmatrix} \begin{bmatrix} d \\ \tilde{w} \end{bmatrix}$$


Conservative solution for RS

$$\|M_{\Delta}\|_{\infty} < \gamma$$


Less conserv. solution for RP by μ

$$\|\mu(M)\|_{\infty} < 1$$


$$\mu_{\Delta}(M) = \frac{1}{\min_{\Delta}(\overline{\sigma}\{\Delta\} : \Delta \in \Delta, \det(I + \Delta M) = 0)}$$



Closed-loop interconnection



Weighting functions



Robust performance results



Iteration	1	2	3
Controller order	11	11	13
D-scale order	0	0	2
γ achieved	1.563	1.014	1.005
Peak value of μ	0.763	0.692	0.727

LPV Modeling



Nonlinear model based design technique (extension of LTI systems) ^{1,2}

$$\dot{x}(t) = A(\rho(t))x(t) + B(\rho(t))u(t)$$

$$y(t) = C(\rho(t))x(t) + D(\rho(t))u(t)$$

$\rho(t)$ should be known
by measurement or
computation

2 well-known techniques:

- affine type: a part of the $\rho(t)$ are equal with the $x(t)$ states
- polytope type: the validity of the model is caught inside a polytope region \implies linear combination of linear models

$$\Sigma(t) \subset \{\Sigma_1, \dots, \Sigma_j\} = \left\{ \sum_{i=1}^j \alpha_i \Sigma_i : \alpha_i \geq 0, \sum_{i=1}^j \alpha_i = 1 \right\} \quad \Sigma_i = \begin{bmatrix} A_i & B_i \\ C_i & D_i \end{bmatrix}$$

1 – F Wu et al. (2000). *Int J Control*, **73**(12): 1104-1114.

2 – W Tan (1997). Applications of Linear Parameter-Varying Control Theory. *MSc. thesis, Berkeley*.

Affine dependency:

$$A(\rho) = A_0 + \rho_1 A_1 + \dots + \rho_N A_N$$

$$B(\rho) = B_0 + \rho_1 B_1 + \dots + \rho_N B_N$$

$$C(\rho) = C_0 + \rho_1 C_1 + \dots + \rho_N C_N$$

$$D(\rho) = D_0 + \rho_1 D_1 + \dots + \rho_N D_N$$

$$\Sigma(t) = \left\{ \Sigma_0 + \sum_{i=1}^N \rho_i \Sigma_i : \rho_i \in [\underline{\rho}_i, \bar{\rho}_i], \dot{\rho}_i \in [\underline{\dot{\rho}}_i, \dot{\bar{\rho}}_i] \right\} \quad \Sigma_i = \begin{bmatrix} A_i & B_i \\ C_i & D_i \end{bmatrix}$$

Three possibilities:

- Jacobi linearization
- state transformation
- function substitution

qALPV \rightarrow Canterbury-model




$$\rho(t) = \begin{bmatrix} \rho_1(t) \\ \rho_2(t) \\ \rho_3(t) \end{bmatrix} = \begin{bmatrix} \frac{S_I(t)Q(t)}{1 + \alpha_G Q(t)} \\ 1 \\ \frac{1}{1 + \alpha_I I(t)} \\ \frac{1}{G(t)} \end{bmatrix}$$

Can be calculated

Measured


qALPV \rightarrow Results



Results



Real clinical dataset ¹



¹ – J. Chase et al. (2008). *J Diab Sci & Techn*, 24(4): 584-594.

Conclusions



- Frequently used ICU model:
 - linear robust μ -synthesis method
 - qALPV + μ -synthesis method
- Nonlinear model based robust control more general
- Further work
 - other ICU Canterbury-models
 - more simulations on real dataset
 - in-silico validations



Thank you for your attention!



8th IFAC Symposium on Biological and Medical Systems
Budapest, Hungary / 29-31 August, 2012

bms.iit.bme.hu